FdaApplication
BLA 125516
Identifiers
- fda_app_no: BLA125516
Properties
| Property | Value |
|---|---|
| applicant_name | United Therapeutics Corporation |
| application_type | BLA |
| approval_date | 2015-03-10 |
Revenue by product
UNITUXIN
| Period | Revenue |
|---|---|
| Q2 2026 | $65.2M |
| Q1 2026 | $53.6M |
| Q4 2025 | $62.3M |
| Q3 2025 | $47.9M |
| Q2 2025 | $58.4M |
| Q1 2025 | $58.2M |
| Q4 2024 | $67.5M |
| Q3 2024 | $61.1M |
| Q2 2024 | $51.7M |
| Q1 2024 | $58.4M |
| Q4 2023 | $54.2M |
| Q3 2023 | $51.3M |
| Q2 2023 | $44.3M |
| Q1 2023 | $49.1M |
| Q4 2022 | $36.7M |
| Q3 2022 | $46.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| UNITUXIN | DINUTUXIMAB | 17.5MG/5ML (3.5MG/ML) | Injection |
1 product